Broadcasted live on August 6, 2026 - Now Available on Demand!
CAR-T therapy has transformed hematological cancer treatment, yet solid tumors remain a complex challenge due to immune suppression, tumor heterogeneity, and limited T-cell persistence. Next-generation CAR-T engineering is driving new advances through innovative receptor design, immune modulation, and functional optimization. This content explores emerging strategies to overcome tumor barriers, enhance targeting and persistence, and expand the potential of precision cellular immunotherapy for solid tumor treatment.
Key Insights Covered
● Navigating Tumor Microenvironment Challenges
● Optimizing CAR-T Cell Engineering
● Improving Immune Recognition and Persistence
● Translating Innovation into Therapeutic Potential
Have Questions?
Contact with our scientific team: events@elabscience.com
Speaker
Dr. Faheem Ahmed Khan
Senior Researcher
Stem Cell & Cancer Research (SCCR) Indonesia
An internationally experienced researcher in stem cell biology, molecular immunology, and cancer immunotherapy, Dr. Faheem Ahmed Khan has held academic, research, and editorial appointments across Indonesia, Thailand, Pakistan, China, and Switzerland, including Associate Professor at Universitas Agung Putra Indonesia (UAPI), Affiliated Researcher at Chulalongkorn University, Thailand, and Associate Editor of Frontiers in Cell and Developmental Biology (Lausanne, Switzerland). His research integrates CRISPR/Cas9 genome engineering and tumor microenvironment modulation to advance next-generation CAR-T cell therapies for solid tumors. Dr. Khan has authored close to 100 Scopus-indexed publications, secured multiple nationally funded research grants, and led international collaborative research that drives innovation in translational cancer immunotherapy.
